The Efficacy of Remdesivir in Reducing SARS-CoV-2 Viral Load and Its Safety on COVID-19 Patients: A Systematic Review

Afifah Fauziyyah, Ratika Rahmasari, Rani Sauriasari


Background: This study aimed to examine the effectiveness of Remdesivir in reducing Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) viral load and its safety for antiviral therapy in Coronavirus disease 2019 (COVID-19) treatment.

Methods: This systematic review used data sources from the PubMed, ProQuest, SpringerLink, and databases for relevant observational and interventional studies during August 2020 to August 2021. Studies evaluating Remdesivir in adults hospitalized for COVID-19 were included in this review. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines.

Results This review found 9 studies that were relevant to the study objectives. In total, 1,088 patients participated as subjects. Three studies demonstrated the effect of remdesivir in reducing SARS-CoV-2 viral load in upper and lower respiratory tract specimens. Six studies demonstrated that remdesivir was safe for use in a variety of baseline conditions (patients on hemodialysis and patients receiving kidney transplantation), had no significant hepatotoxicity, did not increase the risk of acute kidney injury, and did not increase eGFR or systemic symptoms in patients taking remdesivir.

Conclusion: Remdesivir has been shown to reduce SARS-CoV-2 viral load and was safe for use as antiviral therapy in the treatment of COVID-19, but an assessment of randomized controlled trial for the effect of Remdesivir on viral load reduction was not available yet.


COVID-19, Remdesivir, SARS-CoV-2 Viral Load, Safety, Systematic Review

Full Text:



Sciences G. Fact sheet for health care providers emergency use authorization (EUA) of veklury (remdesivir). 2020. p. 1–35.

Lukito JI. Tinjauan Antivirus untuk Terapi COVID-19. 340 Cdk-286. 2020;47(5):PP:342.

Cuenca-Pardo J, Ramos-Gallardo G, Vélez-Benítez E, Álvarez-Díaz C de J, Bucio-Duarte J, Iribarren-Moreno R, et al. The importance of reducing the viral load to diminish the risk of COVID-19 spread. Cirugía Plástica. 2020;30(2):78–93.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.

Choy K, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178.

Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1).

de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117(12):6771–6.

Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–6.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372.

Stang A. scale Critical evaluation of the Newcastle-Ottawa for the assessment of the quality of nonrandomized studies in meta-analyses. 2014;25(9):603–5.

Joo EJ, Ko JH, Kim SE, Kang SJ, Baek JH, Heo EY, et al. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. J Korean Med Sci. 2021;36(11):1–13.

Goldberg E, Ben Zvi H, Sheena L, Sofer S, Krause I, Sklan EH, et al. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel. Clin Microbiol Infect. 2021;27(6):917.e1-917.e4.

Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, et al. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. Ann Intern Med. 2021;174(9):1261–9.

Garcia-Vidal C, Meira F, Cózar-Llistó A, Dueñas G, Puerta-Alcalde P, Garcia-Pouton N, et al. Real-life use of remdesivir in hospitalized patients with COVID-19. Rev Esp Quimioter. 2021;34(2):136–40.

Aiswarya D, Arumugam V, Dineshkumar T, Gopalakrishnan N, Lamech TM, Nithya G, et al. Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance. Kidney Int Reports. 2021;6(3):586–93.

Kalligeros M, Tashima KT, Mylona EK, Rybak N, Flanigan TP, Farmakiotis D, et al. Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. Open Forum Infect Dis. 2020;7(10):1–8.

Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, Cacho J, Cabello Pelegrin S, Melilli E, et al. Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney Int Reports. 2021;6(9):2305–15.

Falcão F, Viegas E, Carmo I, Soares J, Falcao M, Solano M, et al. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: A preliminary report. Eur J Hosp Pharm. 2021;28(5):248–53.

Biancalana E, Chiriacò M, Sciarrone P, Mengozzi A, Mechelli S, Taddei S, et al. Remdesivir, renal function and short-term clinical outcomes in elderly covid-19 pneumonia patients: A single-centre study. Clin Interv Aging. 2021;16:1037–46.

Montastruc F, Thuriot S, Durrieu G. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. Clin Gastroenterol Hepatol. 2020;18(12):2835–6.

Adhikari S, Khadka S, Dahal S, Shrestha DB, Shahi J, Bajgain Y. Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries. Drugs Ther Perspect. 2021;37(1):26–8.

Sun D. Remdesivir for treatment of COVID-19: Combination of pulmonary and IV administration may offer aditional benefit. AAPS J. 2020;22(4):77.

Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Heal. 2021;9:123–7.

ASHP. Assessment of Evidence for COVID-19-Related Treatments : Updated 01 / 29 / 2021. 2021. 1–155 p.

Argyropoulos K V., Serrano A, Hu J, Black M, Feng X, Shen G, et al. Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms. Am J Pathol. 2020;190(9):1881–7.

Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S, Wajnberg A, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8(9):e70.

Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11(1):1–9.

Raharjo AM, Sari ED, Mufida DC. Correlation Between Leukocyte Differential Counts with The Severity and Outcome of Coronavirus Disease 2019 (Covid-19) Patients in Jember. J Respirologi Indones. 2021;41(3):187–95.

Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.

qianqian fan bo zhang, Jie M, Shuyang Z. Safety profile of the antiviral drug remdesivir: An update. Biomed Pharmacother. 2020;130:1–3.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382(24):2327–36.



  • There are currently no refbacks.

Copyright (c) 2022 Afifah Fauziyyah, Ratika Rahmasari, Rani Sauriasari


SINTA Garuda Indonesian Scientific Journal Database (ISJD) Indonesia One Search (IOS) Crossref

ROAD-ISSN Dimensions Google Scholar 


Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845

An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License